Familial Nasopharyngeal Carcinoma 6

98 J-C. LinTable 9.1. Summary of prognostic impact of presenting stage in nasopharyngeal carcinomaSeries No. of cases Treatment T-stageCategory T1 T2 T3 T4Ma et al. (2001a) 621 RT 5-year LFFS 93% 84% 71% 58%Au et al. (2003) 1294 RT 5-year LFFS 82% 82%–77% a 70% 66%5-year MFS 85% 82%–72% 72% 63%Lee et al. (2005b) 2687 RT ± Ch 5-year LFFS 91% 87% 80% 77%Leung et al. (2005) 1070 RT ± Ch 5-year LFFS 88% 87%–82% 69% 69%Ozyar et al. (1999) 90 RT ± Ch 3-year LRFFS 92% 82% 100% 86%Cheng et al. (2006a, b) 630 RT ± Ch 5-year LRFFS 95% 91% 87% 81%Lee et al. (1999) 4515 RT ± ChHong et al. (2000) 411 RT 5-year DSS 83% 82%–65% 48% 22%Chua et al. (2001) 324 RT ± ChHeng et al. (1999) 677 RT 5-year OS 76% 56%–66% 63% 31%Yeh et al. (2005) 849 RT 5-year OS5-year DFSLu et al. (2006) 159 RT 5-year DFS 91% 77% 65% 61%Liu et al. (2008) 749 RT ± Ch OS (HR)LFFS (HR)Mao et al. (2009) 924 RT ± Ch DFS (HR)LFFS (HR)74%69%0.48 *0.270.45 *0.9564%57%1 (T2b)1 (T2b)1 (T2b)1 (T2b)47%39%41%30%1.30 2.43 *1.83 * 3.22 *RT radiotherapy; y year; LFFS local failure-free survival; MFS distant metastasis failure-free survival; OS overall survival; RFSrelapse-free survival; Ch chemotherapy; NFFS neck failure-free survival; DSS disease-specific survival; PFS progression-failuresurvival; CSS cancer-specific survival; LRFFS locoregional failure-free survival; DFS disease-free survival; HR hazard ratioaWhen two numbers appear in one field, it represents data of T2a and T2b for T-classification, N3a and N3b for N-stage, IIAand IIB for overall stage II, IVA and IVB for overall stage IV*Indicates statistically significant difference0.981.962.52 *3.92 a